We are live on ! Find out more
JGUA

John G. Ullman & Associates Portfolio holdings

AUM $824M
1-Year Est. Return 78.19%
This Fund
S&P 500
This Quarter Est. Return
+4.74%
1 Year Est. Return
+78.19%
3 Year Est. Return
+156.18%
5 Year Est. Return
+168.38%
10 Year Est. Return
+388.18%
AUM
$513M
AUM Growth
+$8.91M
Cap. Flow
-$11.6M
Cap. Flow %
-2.27%
Top 10 Hldgs %
35.49%
Holding
121
New
7
Increased
25
Reduced
58
Closed
12

Top Buys

Rank Stock Value
1
XOM icon
ExxonMobil
XOM
+$5.26M
2
NVS icon
Novartis
NVS
+$3.43M
3
SLB icon
SLB Ltd
SLB
+$2.5M
4
GE icon
GE Aerospace
GE
+$2.45M
5
EMR icon
Emerson Electric
EMR
+$2.19M

Sector Composition

Rank Sector Weight
1 Healthcare 25.86%
2 Industrials 20.24%
3 Technology 18.33%
4 Energy 9.89%
5 Utilities 9.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
XOM icon
1
ExxonMobil
XOM
$644B
$25.9M 5.05%
316,041
+66,239
+27% +$5.26M
JNJ icon
2
Johnson & Johnson
JNJ
$646B
$24.3M 4.75%
187,221
-1,414
-0.7% -$187K
EMR icon
3
Emerson Electric
EMR
$86.6B
$22.9M 4.47%
365,001
+36,256
+11% +$2.19M
GLW icon
4
Corning
GLW
$128B
$21.1M 4.1%
703,633
-5,692
-0.8% -$169K
PFE icon
5
Pfizer
PFE
$159B
$16.4M 3.21%
485,672
-5,846
-1% -$188K
SLB icon
6
SLB Ltd
SLB
$85.1B
$15.9M 3.11%
228,474
+37,796
+20% +$2.5M
ABT icon
7
Abbott
ABT
$195B
$14.5M 2.83%
272,032
-3,895
-1% -$195K
LNN icon
8
Lindsay Corp
LNN
$1.16B
$13.9M 2.71%
151,191
-2,034
-1% -$181K
NVS icon
9
Novartis
NVS
$292B
$13.6M 2.65%
176,451
+45,444
+35% +$3.43M
GVA icon
10
Granite Construction
GVA
$5.44B
$13.4M 2.62%
231,709
-2,947
-1% -$155K
MRK icon
11
Merck
MRK
$366B
$13.3M 2.59%
217,113
-3,283
-1% -$199K
INTC icon
12
Intel
INTC
$473B
$12.8M 2.49%
335,815
-3,138
-0.9% -$112K
TEL icon
13
TE Connectivity
TEL
$58.7B
$10.8M 2.11%
130,041
-989
-0.8% -$79.5K
GM icon
14
General Motors
GM
$75.7B
$10.4M 2.03%
258,038
-1,400
-0.5% -$51.1K
IBM icon
15
IBM
IBM
$222B
$9.71M 1.89%
69,975
+5,038
+8% +$702K
TT icon
16
Trane Technologies
TT
$98.8B
$9.01M 1.76%
101,004
+920
+0.9% +$81.3K
WMT icon
17
Walmart Inc
WMT
$820B
$8.82M 1.72%
338,751
-4,392
-1% -$115K
GXP
18
DELISTED
Great Plains Energy Incorporated
GXP
$8.73M 1.7%
288,144
-2,476
-0.9% -$75.8K
BMY icon
19
Bristol-Myers Squibb
BMY
$136B
$8.5M 1.66%
133,406
-466
-0.3% -$27.2K
HON icon
20
Honeywell
HON
$68.9B
$8.16M 1.59%
63,773
-1,771
-3% -$220K
COP icon
21
ConocoPhillips
COP
$157B
$8.06M 1.57%
160,950
+90
+0.1% +$4.04K
AZTA icon
22
Azenta
AZTA
$1.44B
$8.01M 1.56%
263,697
-3,387
-1% -$87.1K
WTS icon
23
Watts Water Technologies
WTS
$12.2B
$7.88M 1.54%
113,891
-1,210
-1% -$77.8K
MSFT icon
24
Microsoft
MSFT
$3.81T
$7.77M 1.52%
104,305
-1,116
-1% -$81.5K
BCE icon
25
BCE
BCE
$21.9B
$7.76M 1.51%
165,765
-1,162
-0.7% -$54.4K

Similar funds

John G. Ullman & Associates's Q3 2017 Portfolio in Review

As of Q3 2017, John G. Ullman & Associates held 121 positions worth $513M, up 1.8% from $504M the previous quarter. Its ten largest holdings account for 35% of the portfolio.

John G. Ullman & Associates's Q3 2017 filing shows 7 new, 25 increased, 58 reduced and 12 closed positions. Its largest new stake was Tortoise Energy Infrastructure Corp: 8,520 shares worth $987K. The largest sale was Calgon Carbon Corp, an estimated $5.95M.

By sector, the portfolio is most concentrated in Healthcare at 26% of assets, up from 25% a quarter earlier, followed by Industrials and Technology.

  • John G. Ullman & Associates's largest Q3 2017 buy was Tortoise Energy Infrastructure Corp: 8,520 shares worth $987K.
  • John G. Ullman & Associates added most to ExxonMobil in Q3 2017, an estimated $5.26M increase.
  • John G. Ullman & Associates's biggest Q3 2017 reduction was State Street SPDR S&P Biotech ETF, cutting an estimated $4.26M.
  • John G. Ullman & Associates fully exited Calgon Carbon Corp in Q3 2017, selling an estimated $5.95M.
  • John G. Ullman & Associates's ten largest holdings make up 35% of its $513M portfolio in Q3 2017.
  • John G. Ullman & Associates opened 7 new positions and closed 12 in Q3 2017.
  • John G. Ullman & Associates's portfolio value rose 1.8% quarter-over-quarter to $513M.

Based on John G. Ullman & Associates's 13F filing for Q3 2017, filed 3 Nov 2017.